Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial

Chemomab Therapeutics Ltd. ( (CMMB) ) has released its Q3 earnings. Here is a breakdown of the information Chemomab Therapeutics Ltd. presented to its investors.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing innovative treatments for fibro-inflammatory diseases, leveraging its unique monoclonal antibody, nebokitug, which targets the soluble protein CCL24. In its latest earnings report, Chemomab highlighted significant progress in its nebokitug program, particularly for primary sclerosing cholangitis (PSC), with the Phase 3 trial design nearing completion following positive feedback from both the FDA and EMA. The company reported a cash position of $10.2 million as of September 30, 2025, and anticipates this will support operations through the end of 2026. Key financial metrics showed a decrease in R&D expenses to $1 million, down from $2.8 million the previous year, primarily due to the completion of the Phase 2 SPRING trial activities. General and administrative expenses remained stable at $0.9 million. Chemomab’s net loss for the quarter was $1.7 million, a significant improvement from the $3.5 million loss in the same period of 2024. Looking ahead, Chemomab is poised to advance its nebokitug Phase 3 trial, with strong regulatory support and potential strategic partnerships, positioning the company to potentially deliver the first disease-modifying therapy for PSC.